Mediterranean diet for CADASIL and CAA
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Mental health clinical trials.
This trial is testing whether a Mediterranean diet (rich in fruits, vegetables, whole grains, and healthy fats) can help people with CADASIL or cerebral amyloid angiopathy (CAA) — two conditions that affect blood vessels in the brain. If you have one of these diagnoses, the study may help you understand how diet can support your brain health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of CADASIL (a genetic disorder that affects small blood vessels in the brain) or possible/probable cerebral amyloid angiopathy (CAA, a condition where proteins build up in brain blood vessels).
- You must agree to let the researchers use your health and diet information for research, with your name removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at brain MRI scans in people with cerebral amyloid angiopathy (a condition where amyloid builds up in brain blood vessels). The goal is to search for “biomarkers,” or measurable scan features, to better understand and detect the disease in some people before symptoms or during symptoms.
This trial is looking at how brain “small blood vessel disease” changes over time and what outcomes to expect. If you have certain symptoms or scan findings from this condition, your care team may compare your prognosis to help guide future treatment planning.
This Phase 2 study tests AMDX-2011P to see if it can help people with cerebral amyloid angiopathy (CAA), a condition where abnormal protein affects blood vessels in the brain. You may be able to join if you have confirmed or likely CAA and a recent brain MRI showing changes from CAA.
This study tests whether the drug LXB (sodium oxybate) can help clear abnormal protein buildup in the brain's small blood vessels (CAA). Participants will take LXB nightly for 8 weeks and have MRIs and spinal taps to measure changes.
This trial tests an experimental medicine called ALN-APP for people with a condition called cerebral amyloid angiopathy (CAA) — a buildup of protein in brain blood vessels that can cause bleeding. The drug aims to reduce this protein and possibly prevent future strokes.
This study looks at how genetic and brain imaging changes relate to symptoms in people with CADASIL, a genetic condition that affects small blood vessels in the brain and can cause strokes. It aims to better understand the disease to improve future care.
Hear when a new Cerebral Amyloid Angiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.